The Oviduct and Serous Cancer Risk Assessment

Abstract

The proposal was designed to address three issues. First could we identify stem cells from the fallopian tube, including from patients with high grade serous cancer (HGSC). Second,could we link the molecular abnormalities in cancer associated stem cells and validate them in pathologic material, specifically in what we feel are stem cell outgrowths or SCOUTs and third could we identify molecular alterations that would place the oviduct or the patient at risk for HGSC. In essence we wished to drill down to the cell of origin and link it to cancer risk, identifying an assay that could predict the presence of cancer by analyzing lower genital tract fluids or other samples.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2015
Accession Number
AD1006313

Entities

People

  • Christopher P Crum

Organizations

  • Brigham and Women's Hospital

Tags

DTIC Thesaurus Topics

  • Cells
  • Chemical Synthesis
  • Chemistry
  • Health Services
  • Medical Personnel
  • Proteins
  • Stem Cells

Fields of Study

  • Medicine

Readers

  • Immunology and Pathology
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.

Technology Areas

  • Biotechnology